1 - 5 toradh á dtaispeáint as 5 toradh san iomlán ar an gcuardach 'Pawel Robak', am iarratais: 0.03s Beachtaigh na torthaí
  1. 1
    Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

    Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib de réir Paweł Robak, Edyta Węgłowska, Izabela Dróżdż, Damian Mikulski, Dariusz Jarych, Magdalena Ferlińska, Ewa Wawrzyniak, Małgorzata Misiewicz, Piotr Smolewski, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak

    Foilsithe / Cruthaithe 2020-01-01
    Faigh an téacs iomlán
    Alt
  2. 2
    Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro

    Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro de réir Jolanta D. Żołnierczyk, Arleta Kaźmierczuk, Paweł Hikisz, Barbara Cebula-Obrzut, Ewa Wawrzyniak, Jerzy Z. Błoński, Małgorzata Misiewicz, Paweł Robak, Piotr Smolewski, Zofia M. Kiliańska

    Foilsithe / Cruthaithe 2015-01-01
    Faigh an téacs iomlán
    Alt
  3. 3
    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study de réir Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Grigoriy Rekhtman, Zvenyslava Masliak, Pawel Robak, Dixie-Lee Esseltine, Huaibao Feng, William Deraedt, Helgi van de Velde, Bertrand Arnulf

    Foilsithe / Cruthaithe 2015-05-01
    Faigh an téacs iomlán
    Alt
  4. 4
    Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

    Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study de réir Fredrik H. Schjesvold, Heinz Ludwig, Sossana Delimpasi, Pawel Robak, Daniel Coriu, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Meletios-Athanasios Dimopoulos, Tamas Masszi, Natalia G. Chernova, Anna Sandberg, Marcus Thuresson, Stefan Norin, Nicolaas A. Bakker, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld

    Foilsithe / Cruthaithe 2024-02-01
    Faigh an téacs iomlán
    Alt
  5. 5
    Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis

    Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis de réir Zuzana Chyra, Tereza Sevcikova, Petr Vojta, Janka Puterova, Lucie Brozova, Katerina Growkova, Jana Filipova, Martina Zatopkova, Sebastian Grosicki, Agnieszka Barchnicka, Wieslaw Wiktor Jedrzejczak, Anna Waszczuk-Gajda, Alexandra Jungova, Aneta Mikulasova, Marian Hajduch, Martin Mokrejs, Ludek Pour, Martin Stork, Lubica Harvanova, Martin Mistrik, Gabor Mikala, Pawel Robak, Anna Czyz, Jakub Debski, Lidia Usnarska-Zubkiewicz, Artur Jurczyszyn, Lukas Stejskal, Gareth Morgan, Fedor Kryukov, Eva Budinska, Michal Simicek, Tomas Jelinek, Matous Hrdinka, Roman Hajek

    Foilsithe / Cruthaithe 2020-05-01
    Faigh an téacs iomlán
    Alt

Uirlisí cuardaigh: